NTRA
Natera Inc
NASDAQ: NTRA · HEALTHCARE · DIAGNOSTICS & RESEARCH
$199.14
-3.06% today
Updated 2026-06-05
Market cap
$30.37B
P/E ratio
—
P/S ratio
12.14x
EPS (TTM)
$-1.61
Dividend yield
—
52W range
$132 – $256
Volume
1.5M
WallStSmart proprietary scores
31
out of 100
Grade: F
Strong Sell
Investment rating
8.0
Growth
A6.8
Quality
B2.0
Profitability
F5.0
Valuation
C+3/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$260.89
+31.01%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
4 Strong Buy13 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $18.03M — positive
+ Revenue growth 38.80% QoQ
+ Debt/equity 0.14x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at -9.05%
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $820.22M | $1.08B | $1.70B | $2.31B | $2.50B | $2.7B |
| Net income | $-547.80M | $-434.80M | $-190.43M | $-208.16M | $-85.09M | — |
| EPS | — | — | — | — | $-1.61 | $-1.52 |
| Free cash flow | $-479.20M | $-286.15M | $69.24M | $109.11M | $18.03M | — |
| Profit margin | -66.79% | -40.16% | -11.22% | -9.03% | -9.05% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2029-06-23 | BROPHY, MICHAEL BURKES | Sale | 12,500 | — |
| 2029-06-08 | BROPHY, MICHAEL BURKES | Sale | 25,000 | — |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Sale | 6,751 | $226.15 |
Peer comparison
Smart narrative
Natera Inc trades at $199.14. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. TTM revenue stands at $2.50B. with profit margins at -9.05%.
Frequently asked questions
What is Natera Inc's stock price?
Natera Inc (NTRA) trades at $199.14, on a P/S of 12.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Natera Inc overvalued?
Natera Inc carries a Smart Value Score of 31/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Natera Inc (NTRA)?
The 12-month analyst consensus target is $260.89, about 31.0% above the current $199.14. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of NTRA by 2030?
Our research-backed model puts the 2030 base case at $178.39, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Natera Inc's revenue?
Natera Inc's trailing twelve-month revenue is $2.50B, and our model projects it reaching about $6.49B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio12.14x
ROE-12.76%
Beta1.54
50D MA$206.64
200D MA$205.44
Shares out0.14B
Float0.14B
Short ratio—
Avg volume1.5M
Performance
1 week+0.00%
1 month+15.53%
3 months+14.62%
YTD-6.02%
1 year—
3 years—
5 years—